Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE4
Total Enrollment
339 participants
Study Classification
INTERVENTIONAL
Study Start Date
2014-06-01
Study Completion Date
2019-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Rationale: Seroma formation and its sequelae form the mainstay of complications in breast cancer surgery. Seroma has an incidence of 3% to 85%. Complications vary from delayed wound healing, infection, skin flap necrosis, patient discomfort and repeated visits to the out patient clinic. The key to reducing seroma formations seems to partly lie in the obliteration of dead space. The use of electrocautery has been demonstrated to increase seroma formation following mastectomy, however no other surgical devices (laser scalpel, argon diathermy and ultrasonic scalpel) or substances have proven to be superior in seroma reduction.
No prospective randomized controlled trials have been able to demonstrate which techniques are superior in reducing seroma and as a consequence patient discomfort in patients undergoing mastectomy. In a previous retrospective observational study these investigators demonstrated that mastectomy flap fixation significantly reduced seroma formation and the number of seroma aspirations. In a pilot study that was recently performed in one of the investigators hospitals, ARTISS tissue glue was used for skin flap fixation and showed promising results. The investigators hypothesize that obliteration of the dead space following mastectomy will significantly reduce seroma formation, its complications and the discomfort it causes patients undergoing mastectomy.
No prospective randomized controlled trials have been able to demonstrate which techniques are superior in reducing seroma and as a consequence patient discomfort in patients undergoing mastectomy. In a previous retrospective observational study these investigators demonstrated that mastectomy flap fixation significantly reduced seroma formation and the number of seroma aspirations. In a pilot study that was recently performed in one of the investigators hospitals, ARTISS tissue glue was used for skin flap fixation and showed promising results. The investigators hypothesize that obliteration of the dead space following mastectomy will significantly reduce seroma formation, its complications and the discomfort it causes patients undergoing mastectomy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
fixAtion of skiN Flaps After Mastectomy Using ruNning or Interrupted suturEs for Combatting Seroma
NCT05941351
Seroma
NOT_YET_RECRUITING
NA
The QUILT Study: Quilting Sutures in Patients Undergoing Breast Cancer Surgery
NCT05272904
Seroma
UNKNOWN
NA
Fibrin Sealant in Preventing Fluid Build Up During Surgery in Patients Undergoing Breast Reconstruction
NCT01649505
Breast Cancer
Perioperative/Postoperative Complications
TERMINATED
NA
ELectrosurgical Bipolar Devices VS Conventional Electro-cauterization in Breast Surgery
NCT03166384
Seroma as Procedural Complication
COMPLETED
NA
Seroma at the Donor Site of the TRAM Flap, With or Without Quilting Suture: A Comparative Study Using Ultrasound
NCT01358786
Seroma
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. INTRODUCTION AND RATIONALE
Seroma formation is a common side effect after surgery for breast cancer, with an incidence of 3% to 85%. Seroma is a collection of serous fluid that contains blood plasma and/ or lymph fluid. Some surgeons regard seroma formation as a necessary evil after breast cancer surgery. Seroma formation and its sequelae form the mainstay of complications in breast cancer surgery. Complications vary from delayed wound healing, infection, skin flap necrosis, patient discomfort and repeated visits to the out patient clinic to deal with seroma and its sequelae.
The key to reducing seroma formations seems to partly lie in the obliteration of dead space. However, the techniques used to achieve this goal are subjects of much controversy and debate. In a randomized controlled study it was difficult to elucidate whether reducing the dead space or ligation of lymphatics or a combination of both were responsible of reduction of seroma formation.
The use of electrocautery has been demonstrated to increase seroma formation following mastectomy, however no other surgical devices (laser scalpel, argon diathermy and ultrasonic scalpel) or substances have proven to be superior in seroma reduction. Seroma formation after axillary dissection for breast cancer cannot be avoided but hopefully it can be minimized by mechanical dead space closure. This systematic review highlights the fact that seroma formation is multifactorial and prevention of seroma is difficult at present. Certain prospective trials have been performed that demonstrate that flap anchoring and therefore dead space reduction could be very beneficial. The trial performed by Laurence et al analysed flap fixation and closed suction drainage. In this study there was no difference in seroma rates, but patients without drains were discharged earlier. In the trial performed by Sakkary et al the amount of fluid drained was significantly less in the flap fixation group however patient discomfort (seroma aspirations and out patient visits) were not assessed.
A Cochrane review was published in 2013 regarding Fibrin Glue (Tissuecol), Fibrin Glue did not influence the incidence of postoperative seroma, the mean volume of seroma, wound infections, complications and the length of hospital stays in people undergoing breast cancer surgery. Due to significant methodological and clinical diversity among the included studies this conclusion may be considered weak and biased. Therefore, a major multicentre and high-quality RCT is required to validate these findings. ARTISS tissue glue is a two-component fibrin sealant matrix of human fibrinogen and human thrombin wich has the advantage of setting in 60 seconds. This means that the surgeon has 60 seconds to correctly position the skin flaps before the tissue sealant sets,
The investigators hypothesize that obliteration of the dead space following mastectomy will significantly reduce seroma formation. This study aims to reduce seroma formation after mastectomy, proving that obliteration of dead space following mastectomy is vital in preventing seroma formation and its sequelae.
The investigators current standard of treatment for patients undergoing mastectomy in Atrium Medical Centre Heerlen is flap fixation using interrupted Vicryl sutures and closed suction drainage. In Orbis Medical Centre Sittard current standard of wound closure in patients undergoing mastectomy is ARTISS Tissue Glue.
A retrospective study (13-N-77) has been conducted in our centre in which flap fixation seemed to be an effective surgical technique in reducing dead space and therefore seroma formation in patients undergoing mastectomy for invasive breast cancer. Patients undergoing flap fixation required fewer seroma aspirations and had fewer seroma related complications (infection).
2. OBJECTIVES
Primary Objective:
To assess:
1\. The number of seroma aspirations
Secondary Objective(s):
To assess:
1. The number of out patient clinic visits
2. Infection rate
3. Shoulder function
4. Cosmesis
5. Quality of life, costs and cost-effectiveness (cost/QALY)
3\. STUDY DESIGN
Study design is a double-blind randomized controlled trial. All patients are \> 18 years and will be enrolled after obtaining informed consent in the surgical out patient clinics of Zuyderland Medical Center (Heerlen and Sittard), Maastricht University Medical Center, St Jans Gasthuis, Weert and Albert Schweitser Hospital, Dordrecht. All patients have an indication to undergo mastectomy due to invasive breast cancer or DCIS.
Follow up will be performed until 1 year after surgery. Patients will be evaluated in the out patient clinic 2 weeks, 6 weeks, 3 months, 6 months and 12 months postoperatively.
Study population:
Female patients \> 18 years diagnosed with invasive breast cancer or DCIS with an indication to perform mastectomy
Intervention:
1. Conventional mastectomy with closed suction drainage
2. Mastectomy with flap fixation using absorbable sutures and closed suction drainage
3. Mastectomy with flap fixation using ARTISS tissue glue and closed suction drainage
Main study parameters/endpoints:
Primary endpoint: Number of seroma aspirations
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients will be informed about the study before inclusion in the out patient clinic. Informed consent will be obtained in the out patient clinic a week after patients were initially informed. Postoperative check ups will de done more frequently.
Standard postoperative check ups:
2 weeks, 3 months, 12 months
Additional study postoperative check ups:
6 weeks, 6 months Therefore patients will be required to undergo two additional check ups. During out patients' visits, patients will hand in questionnaires regarding shoulder function and a questionnaire scale regarding cosmesis.
Patients will be clinically examined as they usually would be.
Out-patient follow up identical for all three groups
2 weeks post operatively, DASH + cosmesis questionnaire, clinical assessment seroma 6 weeks post operatively, DASH + cosmesis questionnaire + EQ-5D, clinical assessment seroma 3 months post operatively, DASH + cosmesis questionnaire + EQ-5D + cost questionnaire, clinical assessment seroma 6 months post operatively, DASH + cosmesis questionnaire + EQ-5D + cost questionnaire, clinical assessment seroma 12 months post operatively, DASH + cosmesis questionnaire +EQ-5D + cost questionnaire, clinical assessment seroma
EXIT FROM TRIAL 1 YEAR POST OPERATIVELY 4. STUDY POPULATION 4.1 Population (base ) All patients will be recruited from the surgical breast cancer clinic after evaluation for invasive breast cancer or DCIS. Patients will be recruited from two breast cancer clinics, treating 500 patients annually for breast cancer. Patients undergoing mastectomy or modified radical mastectomy are eligible for inclusion.
4.2 Inclusion criteria Older than 18 years Female sex Indication for mastectomy or modified radical mastectomy
4.3 Exclusion criteria Patients undergoing breast conserving therapy Patients undergoing direct breast reconstruction Unable to comprehend implications and extent of study and sign for informed consent
4.4 Sample size calculation The number of seroma aspirations is not normally distributed. Therefore, sample size estimations based on normally distributed continuous variables cannot be used. It is possible to use formulas based on non-parametric analysis methods, estimating the chance of a random patient in the treatment group having fewer aspirations than a random patient in the control group. However, since the majority of patients will have the same number of aspirations (i.e. 0), this method of sample size estimation does not seem to be applicable to our study.
Sample size estimation based on ordinal regression is in line with the data distribution and limited possibilities (maximum number of aspirations in the observational retrospective study was 4) of the outcome variable (Walters SJ. Health Qual Life Outcomes 2004: 2(1); 26). Using alpha=0.025 (correction for 2 comparisons with 3 study groups), beta=0.10, and a proportional odds ratio=2.67 (corresponding to an absolute difference of 20% in the need for seroma punctions), the sample size is estimated at 112 patients per study group.
5\. TREATMENT OF SUBJECTS Group 1: conventional treatment and closed suction drainage Group 2: flap fixation with vicryl sutures and closed suction drainage Group 3: Artiss tissue glue and closed suction drainage
Seroma formation is a common side effect after surgery for breast cancer, with an incidence of 3% to 85%. Seroma is a collection of serous fluid that contains blood plasma and/ or lymph fluid. Some surgeons regard seroma formation as a necessary evil after breast cancer surgery. Seroma formation and its sequelae form the mainstay of complications in breast cancer surgery. Complications vary from delayed wound healing, infection, skin flap necrosis, patient discomfort and repeated visits to the out patient clinic to deal with seroma and its sequelae.
The key to reducing seroma formations seems to partly lie in the obliteration of dead space. However, the techniques used to achieve this goal are subjects of much controversy and debate. In a randomized controlled study it was difficult to elucidate whether reducing the dead space or ligation of lymphatics or a combination of both were responsible of reduction of seroma formation.
The use of electrocautery has been demonstrated to increase seroma formation following mastectomy, however no other surgical devices (laser scalpel, argon diathermy and ultrasonic scalpel) or substances have proven to be superior in seroma reduction. Seroma formation after axillary dissection for breast cancer cannot be avoided but hopefully it can be minimized by mechanical dead space closure. This systematic review highlights the fact that seroma formation is multifactorial and prevention of seroma is difficult at present. Certain prospective trials have been performed that demonstrate that flap anchoring and therefore dead space reduction could be very beneficial. The trial performed by Laurence et al analysed flap fixation and closed suction drainage. In this study there was no difference in seroma rates, but patients without drains were discharged earlier. In the trial performed by Sakkary et al the amount of fluid drained was significantly less in the flap fixation group however patient discomfort (seroma aspirations and out patient visits) were not assessed.
A Cochrane review was published in 2013 regarding Fibrin Glue (Tissuecol), Fibrin Glue did not influence the incidence of postoperative seroma, the mean volume of seroma, wound infections, complications and the length of hospital stays in people undergoing breast cancer surgery. Due to significant methodological and clinical diversity among the included studies this conclusion may be considered weak and biased. Therefore, a major multicentre and high-quality RCT is required to validate these findings. ARTISS tissue glue is a two-component fibrin sealant matrix of human fibrinogen and human thrombin wich has the advantage of setting in 60 seconds. This means that the surgeon has 60 seconds to correctly position the skin flaps before the tissue sealant sets,
The investigators hypothesize that obliteration of the dead space following mastectomy will significantly reduce seroma formation. This study aims to reduce seroma formation after mastectomy, proving that obliteration of dead space following mastectomy is vital in preventing seroma formation and its sequelae.
The investigators current standard of treatment for patients undergoing mastectomy in Atrium Medical Centre Heerlen is flap fixation using interrupted Vicryl sutures and closed suction drainage. In Orbis Medical Centre Sittard current standard of wound closure in patients undergoing mastectomy is ARTISS Tissue Glue.
A retrospective study (13-N-77) has been conducted in our centre in which flap fixation seemed to be an effective surgical technique in reducing dead space and therefore seroma formation in patients undergoing mastectomy for invasive breast cancer. Patients undergoing flap fixation required fewer seroma aspirations and had fewer seroma related complications (infection).
2. OBJECTIVES
Primary Objective:
To assess:
1\. The number of seroma aspirations
Secondary Objective(s):
To assess:
1. The number of out patient clinic visits
2. Infection rate
3. Shoulder function
4. Cosmesis
5. Quality of life, costs and cost-effectiveness (cost/QALY)
3\. STUDY DESIGN
Study design is a double-blind randomized controlled trial. All patients are \> 18 years and will be enrolled after obtaining informed consent in the surgical out patient clinics of Zuyderland Medical Center (Heerlen and Sittard), Maastricht University Medical Center, St Jans Gasthuis, Weert and Albert Schweitser Hospital, Dordrecht. All patients have an indication to undergo mastectomy due to invasive breast cancer or DCIS.
Follow up will be performed until 1 year after surgery. Patients will be evaluated in the out patient clinic 2 weeks, 6 weeks, 3 months, 6 months and 12 months postoperatively.
Study population:
Female patients \> 18 years diagnosed with invasive breast cancer or DCIS with an indication to perform mastectomy
Intervention:
1. Conventional mastectomy with closed suction drainage
2. Mastectomy with flap fixation using absorbable sutures and closed suction drainage
3. Mastectomy with flap fixation using ARTISS tissue glue and closed suction drainage
Main study parameters/endpoints:
Primary endpoint: Number of seroma aspirations
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients will be informed about the study before inclusion in the out patient clinic. Informed consent will be obtained in the out patient clinic a week after patients were initially informed. Postoperative check ups will de done more frequently.
Standard postoperative check ups:
2 weeks, 3 months, 12 months
Additional study postoperative check ups:
6 weeks, 6 months Therefore patients will be required to undergo two additional check ups. During out patients' visits, patients will hand in questionnaires regarding shoulder function and a questionnaire scale regarding cosmesis.
Patients will be clinically examined as they usually would be.
Out-patient follow up identical for all three groups
2 weeks post operatively, DASH + cosmesis questionnaire, clinical assessment seroma 6 weeks post operatively, DASH + cosmesis questionnaire + EQ-5D, clinical assessment seroma 3 months post operatively, DASH + cosmesis questionnaire + EQ-5D + cost questionnaire, clinical assessment seroma 6 months post operatively, DASH + cosmesis questionnaire + EQ-5D + cost questionnaire, clinical assessment seroma 12 months post operatively, DASH + cosmesis questionnaire +EQ-5D + cost questionnaire, clinical assessment seroma
EXIT FROM TRIAL 1 YEAR POST OPERATIVELY 4. STUDY POPULATION 4.1 Population (base ) All patients will be recruited from the surgical breast cancer clinic after evaluation for invasive breast cancer or DCIS. Patients will be recruited from two breast cancer clinics, treating 500 patients annually for breast cancer. Patients undergoing mastectomy or modified radical mastectomy are eligible for inclusion.
4.2 Inclusion criteria Older than 18 years Female sex Indication for mastectomy or modified radical mastectomy
4.3 Exclusion criteria Patients undergoing breast conserving therapy Patients undergoing direct breast reconstruction Unable to comprehend implications and extent of study and sign for informed consent
4.4 Sample size calculation The number of seroma aspirations is not normally distributed. Therefore, sample size estimations based on normally distributed continuous variables cannot be used. It is possible to use formulas based on non-parametric analysis methods, estimating the chance of a random patient in the treatment group having fewer aspirations than a random patient in the control group. However, since the majority of patients will have the same number of aspirations (i.e. 0), this method of sample size estimation does not seem to be applicable to our study.
Sample size estimation based on ordinal regression is in line with the data distribution and limited possibilities (maximum number of aspirations in the observational retrospective study was 4) of the outcome variable (Walters SJ. Health Qual Life Outcomes 2004: 2(1); 26). Using alpha=0.025 (correction for 2 comparisons with 3 study groups), beta=0.10, and a proportional odds ratio=2.67 (corresponding to an absolute difference of 20% in the need for seroma punctions), the sample size is estimated at 112 patients per study group.
5\. TREATMENT OF SUBJECTS Group 1: conventional treatment and closed suction drainage Group 2: flap fixation with vicryl sutures and closed suction drainage Group 3: Artiss tissue glue and closed suction drainage
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Seroma
Aspiration
Breast Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Study design is a double-blind randomized controlled trial. All patients are \> 18 years and will be enrolled after obtaining informed consent in the surgical out patient clinics of Zuyderland Medical Center (Heerlen and Sittard), Maastricht University Medical Center, St Jans Gasthuis, Weert and Albert Schweitser Hospital, Dordrecht. All patients have an indication to undergo mastectomy due to invasive breast cancer or DCIS.
Follow up will be performed until 1 year after surgery. Patients will be evaluated in the out patient clinic 2 weeks, 6 weeks, 3 months, 6 months and 12 months postoperatively.
Follow up will be performed until 1 year after surgery. Patients will be evaluated in the out patient clinic 2 weeks, 6 weeks, 3 months, 6 months and 12 months postoperatively.
Primary Study Purpose
TREATMENT
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
Randomisation is achieved using a web based randomization programme (RANDI2). Randomization will take place on the day of surgery, after the start of the operation and 30 minutes before wound closure. Blocked randomisation will take place with randomly selected block sizes (6/9/12) with an allocation ratio of 1:1:1. Randomisation will be stratified per site. Both patients and surgeons will be blinded. Patients will be informed preoperatively that their post-operative check ups will NOT be performed by the surgeon that performed the surgery. Randomisation will take place 30 minutes before wound closure in the operating theatre. Post-operatively, patients will not be evaluated by their own surgeon. The OR report will contain the following information (in Dutch) so as to ensure that blinding of the physicians will not be compromised.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
conventional wound closure
The skin flaps will not undergo further treatment in this group.
Group Type
ACTIVE_COMPARATOR
Conventional
Intervention Type
PROCEDURE
Conventional closure after mastectomy
flap fixation with vicryl sutures
The skin flaps will be sutured on to the pectoral muscle after having performed the mastectomy.
Group Type
EXPERIMENTAL
vicryl sutures
Intervention Type
PROCEDURE
Flap fixation with vicryl sutures after mastectomy
Artiss tissue glue
ARTISS tissue glue will be applied to the skin flaps after mastectomy
Group Type
EXPERIMENTAL
Artiss
Intervention Type
DRUG
Application of ARTISS Glue to skin flaps after mastectomy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Artiss
Application of ARTISS Glue to skin flaps after mastectomy
Intervention Type
DRUG
vicryl sutures
Flap fixation with vicryl sutures after mastectomy
Intervention Type
PROCEDURE
Conventional
Conventional closure after mastectomy
Intervention Type
PROCEDURE
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Artiss glue
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Older than 18 years
* Female sex
* Indication for mastectomy or modified radical mastectomy
* Female sex
* Indication for mastectomy or modified radical mastectomy
Exclusion Criteria
* Patients undergoing breast conserving therapy
* Patients undergoing direct breast reconstruction
* Unable to comprehend implications and extent of study and sign for informed consent
* Patients undergoing direct breast reconstruction
* Unable to comprehend implications and extent of study and sign for informed consent
Minimum Eligible Age
18 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zuyderland Medisch Centrum
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
James van Bastelaar
MD
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
James van Bastelaar, MD
Role: PRINCIPAL_INVESTIGATOR
Zuyderland Medisch Centrum
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zuyderland Medisch Centrum
Sittard, Limburg, Netherlands
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Netherlands
References
Explore related publications, articles, or registry entries linked to this study.
van Bastelaar J, Beckers A, Snoeijs M, Beets G, Vissers Y. Flap fixation reduces seroma in patients undergoing mastectomy: a significant implication for clinical practice. World J Surg Oncol. 2016 Mar 8;14:66. doi: 10.1186/s12957-016-0830-8.
Reference Type
RESULT
de Rooij L, van Kuijk SMJ, Granzier RWY, Hintzen KFH, Heymans C, Theunissen LLB, von Meyenfeldt EM, van Essen JA, van Haaren ERM, Janssen A, Vissers YLJ, Beets GL, van Bastelaar J. Reducing Seroma Formation and Its Sequelae After Mastectomy by Closure of the Dead Space: A Multi-center, Double-Blind Randomized Controlled Trial (SAM-Trial). Ann Surg Oncol. 2021 May;28(5):2599-2608. doi: 10.1245/s10434-020-09225-8. Epub 2020 Oct 19.
Reference Type
DERIVED
van Bastelaar J, Granzier R, van Roozendaal LM, Beets G, Dirksen CD, Vissers Y. A multi-center, double blind randomized controlled trial evaluating flap fixation after mastectomy using sutures or tissue glue versus conventional closure: protocol for the Seroma reduction After Mastectomy (SAM) trial. BMC Cancer. 2018 Aug 17;18(1):830. doi: 10.1186/s12885-018-4740-8.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14-T-21
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Comparison Of The 3M TM S Surgical Skin Closure System To The Standard Vicryl Suture Closure of Sternotomy Incisions During Cardiac Surgery
NCT00576745
COMPLETED
PHASE1
Seroma Prevention After Body Contouring Procedures
NCT03190876
UNKNOWN
NA
Randomized Controlled Trial of Subcuticular Skin Closure Versus Steri-strip S Closure
NCT00727025
COMPLETED
NA
SAVE Studie- SArcoma Surgery With Vacuum Enhanced Wound Treatment Randomised Study to Evaluate the Wound Management in Sarcoma Surgery
NCT06889532
RECRUITING
NA
Fibrin Glue in Inguinal Lymphadenectomy
NCT04666051
COMPLETED
NA
Adhesive Tape in Episiotomy Repair
NCT02608671
COMPLETED
PHASE4
SEAM Trial: Sutureless End to End Anastomosis by Magnetic Compression
NCT05046730
TERMINATED
NA
Laparoscopic Repair of Cesarean Scar Niche
NCT04307524
UNKNOWN
PHASE2/PHASE3
Suture Closure Trial
NCT05261425
ACTIVE_NOT_RECRUITING
NA
Evaluating the Effect of Surgical Drain Securement on Patient Quality of Life and Postoperative Drain-related Complications
NCT06916286
RECRUITING
NA
Excision of Strip of Deep Fascia to Reduce Seroma Formation and Extrusion of Tissue Expanders
NCT00968318
COMPLETED
NA
ZIPS Study - Zip Incision Approximation vs. STAPLE
NCT02255877
WITHDRAWN
PHASE4
Zip® Surgical Skin Closure Device vs. Staples for Skin Closure in Subjects Having Undergone Bilateral Knee Arthroplasty
NCT02460172
COMPLETED
NA
Staples Versus Dermabond for Closure of the Skin After Cesarean Section
NCT01261715
UNKNOWN
PHASE4
The Use of PrevenaTM on Clean Closed Sternal Midline Incisions in Subjects at High Risk for Surgical Site Occurrences.
NCT02195310
TERMINATED
NA
Early Bandage Removal Post-Cesarean Delivery
NCT01867567
COMPLETED
NA
Improving Sternal Healing After Cardiac Surgery: Sternal Wire vs ZIPFIX
NCT03289104
WITHDRAWN
NA
NoSeal Trial: Comparing Sealants Versus No Sealant for Preventing CSF Leak After Endonasal Skull Base Surgery
NCT07216157
RECRUITING
NA
Sutures Versus Glue in Laparoscopic Port Site Closure.
NCT03843866
UNKNOWN
NA
Effect of Replacing Buried Sutures With Tissue Adhesive on Aesthetic Outcome of Surgical Wounds.
NCT03425370
TERMINATED
NA
Study to Determine the Utility of Wound Vacuum Assisted Closure (VAC) Compared to Conventional Saline Dressing Changes
NCT00121537
TERMINATED
NA
Study of Sutures Versus Staples for Skin Closure After Surgical Procedures of Hip
NCT00273715
COMPLETED
PHASE4
Suture Versus Glue (Dermabond) Closure During Cesarean Delivery
NCT02831946
UNKNOWN
PHASE4
Seal-G/ Seal-G MIST Long-Term Follow-up PMCF (Continue) Study
NCT07100886
NOT_YET_RECRUITING
Vicryl Plus and Monocryl Plus in Breast Surgery
NCT00830271
COMPLETED
NA